GlaxoSmithKline Sumbits Application For Shingles Treatment Shingrix
November 25 2016 - 8:10AM
Dow Jones News
LONDON-- GlaxoSmithKline PLC (GSK.LN) Friday said it plans to
submit a marketing authorization application to the European
Medicines Agency for its candidate shingles vaccine Shingrix to be
used in people aged 50 years or over.
Shares at 1338 GMT, up 14 pence, or 1%, at 1,538 pence valuing
the company at GBP75 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
November 25, 2016 08:55 ET (13:55 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024